| Market Cap | $4.03B+72.3% |
| Revenue (ttm) | $238.66M |
| Net Income | -$79.02M |
| EPS | $0.67 |
| Shares Out | 87.89M |
| PE Ratio | 68.49 |
| Forward PE | -173.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,332,668 |
| Open | $46.37 |
| Previous Close | $47.07 |
| Day's Range | $44.92 - $47.60 |
| 52-Week Range | $20.13 - $60.66 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | $65.00(+41.64%) |
| Earnings Date | Nov 12, 2026 |
About HTFL
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient's heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart's arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies. Its platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. HeartFlow, Inc. was formerly known as Cardiovascular Simulation, Inc. and changed its name to HeartFlow, Inc. in May 2009. The company was incorporated in 2007 and is headquartered in San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating HTFL in the last 3 months, one vote each. Issuer-paid research is not counted.
$HTFL stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in HTFL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by HTFL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
HTFL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New HTFL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to HTFL from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from HTFL’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 revenue surged 57% with guidance raised; analyst upgraded price target $45→$70 with Buy maintained; adjusted losses narrowed despite GAAP loss.
Recent Insider Activity
Insider Score Trend Over Time
-38.0 since Aug 21Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| HEAL | Global X HealthTech ETF | 3.21% |
| HLTH | Tema Healthcare AI ETF | 1.90% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 1.51% |
| EKG | First Trust Nasdaq Lux Digital Health Solutions ETF | 1.21% |
| HYP | Golden Eagle Dynamic Hypergrowth ETF | 1.21% |
| FYC | First Trust Small Cap Growth AlphaDEX Fund | 0.63% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.52% |
| IHF | iShares U.S. Healthcare Providers ETF | 0.49% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.47% |
| AIMS | Acuitas Small Cap Active ETF | 0.42% |
| MMSC | First Trust Multi-Manager Small Cap Opportunities ETF | 0.37% |
| FESM | Fidelity Enhanced Small Cap ETF | 0.37% |
Weight is the stock’s share of each fund’s holdings.
